The second Department of Respiration, Xi'an Children's Hospital, Xi'an, China.
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):119-127. doi: 10.18502/ijaai.v21i2.9220.
Asthma is a respiratory disease; involving millions of people worldwide. The main cause of asthma is allergy and immune response dysregulation. The effects of azithromycin and doxycycline as asthma-controlling drugs were evaluated in this study. Mice asthma model was produced and asthmatic mice were treated with azithromycin (75 mg/kg, orally) and doxycycline (20 mg/kg, orally). Eosinophils and neutrophils count, interleukin (IL)-4, IL-5, IL-12, IL-13, and total immunoglobulin E (IgE) levels were measured. Histological study and evaluating the genes expression of Muc5ac, Muc5b, IL-33, COX2, MYD88, and TRAF6 were performed. Azithromycin and doxycycline did not affect eosinophil and neutrophil percentage, IL-4, IL-5, IL-12, and total IgE levels, peribronchial and perivascular inflammation, goblet cell hyperplasia, and gene expression of MYD88, TRAF6, and COX2. Treatment with azithromycin significantly decreased IL-13 level, mucus secretion, and gene expression of IL-33, Muc5ac, and Muc5b; compared to the non-treated asthma group. Azithromycin administration controls mucus secretion and inflammation. Azithromycin therapy and not doxycycline might be an effective adjuvant option in asthma with reducing mucus in the airway.
哮喘是一种呼吸系统疾病，全球有数以百万计的患者。哮喘的主要病因是过敏和免疫反应失调。本研究评估了阿奇霉素和强力霉素作为哮喘控制药物的效果。通过建立哮喘小鼠模型，用阿奇霉素（75mg/kg，口服）和强力霉素（20mg/kg，口服）对哮喘小鼠进行治疗。检测嗜酸性粒细胞和中性粒细胞计数、白细胞介素（IL）-4、IL-5、IL-12、IL-13 和总免疫球蛋白 E（IgE）水平。进行组织学研究，并评估 Muc5ac、Muc5b、IL-33、COX2、MYD88 和 TRAF6 的基因表达。阿奇霉素和强力霉素不影响嗜酸性粒细胞和中性粒细胞百分比、IL-4、IL-5、IL-12 和总 IgE 水平、支气管周围和血管周围炎症、杯状细胞增生以及 MYD88、TRAF6 和 COX2 的基因表达。与未经治疗的哮喘组相比，阿奇霉素治疗显著降低了 IL-13 水平、粘液分泌以及 IL-33、Muc5ac 和 Muc5b 的基因表达。阿奇霉素治疗可控制粘液分泌和炎症。阿奇霉素治疗而不是强力霉素治疗可能是一种有效的哮喘辅助治疗选择，可减少气道中的粘液。
